Evidence map›Paper›PMID 41074903›Full record

Trial reportClinical obesity2026

Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes.

Christopher D Coleman, Jessica R Kiel, Orsolya M Palacios, Marjorie Bell, Meredith L Wilcox, Kevin C Maki, Jessica L Unick, Satya S Jonnalagadda

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christopher D ColemanDepartment of Scientific and Clinical Affairs, Medifast Inc., Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-0580-0122
Jessica R KielDepartment of Scientific and Clinical Affairs, Medifast Inc., Baltimore, Maryland, USA.
Orsolya M PalaciosMidwest Biomedical Research, Addison, Illinois, USA.
Marjorie BellMidwest Biomedical Research, Addison, Illinois, USA.
Meredith L WilcoxMidwest Biomedical Research, Addison, Illinois, USA.
Kevin C MakiMidwest Biomedical Research, Addison, Illinois, USA.
Jessica L UnickThe Miriam Hospital's Weight Control and Diabetes Research Center, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
Satya S JonnalagaddaDepartment of Scientific and Clinical Affairs, Medifast Inc., Baltimore, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This secondary analysis assessed potential factors associated with achieving ≥ 5% or ≥ 10% weight loss among adults in a clinical trial evaluating two commercial weight loss programmes. Participants [n = 124, 45.7 (13.1) years, 20.2% male, BMI 34.4 (3.4) kg/m

Indexed as

ObesityWeight LossWeight Reduction ProgramsAdultBody Mass IndexFemaleHumansLife StyleMaleMiddle AgedTreatment Outcomeearly weight lossmeal replacementsresponders

Identifiers

PMID41074903
PMCPMC12705255

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.